Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial
Authors:
- Maureen G. ConlanMCMaureen G. Conlan
- SPRINT Study GroupSGSPRINT Study Group
- 13 February 2006
- journal article
- Published by Wiley in Transfusion
- Vol. 46 (4) , 562-571
Abstract
BACKGROUND: A photochemical treatment (PCT) system has been developed to inactivate a broad spectrum of pathogens and white blood cells in platelet (PLT) products. The system comprises PLT additive solution (PAS III), amotosalen HCl, a compound adsorption device (CAD), a microprocessor‐controlled ultraviolet A light source, and a commercially assembled system of interconnected plastic containers.STUDY DESIGN AND METHODS: A clinical prototype of the PCT system was used in a large, randomized, controlled, double‐blind, Phase III clinical trial (SPRINT) that compared the efficacy and safety of PCT apheresis PLTs to untreated apheresis PLTs. The ability of multiple users was assessed in a blood center setting to perform the PCT and meet target process specifications.RESULTS: Each parameter was evaluated for 2237 to 2855 PCT PLT products. PCT requirements with respect to mean PLT dose, volume, and plasma content were met. Transfused PCT PLT products contained a mean of 3.6 × 1011 ± 0.7 × 1011 PLTs. The clinical process, which included trial‐specific samples, resulted in a mean PLT loss of 0.8 × 1011 ± 0.6 × 1011 PLTs per product. CAD treatment effectively reduced the amotosalen concentration from a mean of 31.9 ± 5.3 µmol per L after illumination to a mean of 0.41 ± 0.56 µmol per L after CAD. In general, there was little variation between sites for any parameter.CONCLUSIONS: The PCT process was successfully implemented by 12 blood centers in the United States to produce PCT PLTs used in a prospective, randomized trial where therapeutic efficacy of PCT PLTs was demonstrated. Process control was achieved under blood bank operating conditions.Keywords
This publication has 26 references indexed in Scilit:
- Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialBlood, 2004
- First report of human immunodeficiency virus transmission via an RNA‐screened blood donationVox Sanguinis, 2004
- NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissionsTransfusion, 2004
- Improving the bacteriological safety of platelet transfusionsTransfusion Medicine Reviews, 2004
- Practical Experience of Implementing the INTERCEPT™ Blood System for Buffy Coat Platelets in a Blood CenterTransfusion Medicine and Hemotherapy, 2004
- Progress Toward a Pathogen-Free Blood SupplyClinical Infectious Diseases, 2003
- Photochemical Treatment of Platelet Concentrates with a Novel Psoralen and UVA to Enhance the Safety of Platelet TransfusionsaTransfusion Medicine and Hemotherapy, 1998
- Strategies for viral inactivationCurrent Opinion in Hematology, 1995
- Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV‐1 antibody screeningTransfusion, 1991
- Survival of Borrelia burgdorferi in blood productsTransfusion, 1989